Nivolumab Extends Survival for Patients With the Most Common Lung Cancer
02 Jun 2015 Oncology

An introduction to ASCO 2015 by the 2014-15 president, Peter Paul Yu, MD, FACP, FASCO
02 Jun 2015 Oncology

PARP inhibitors and the EMBRACA study of talazoparib in BRCA-related metastatic breast cancer
21 May 2015 Oncology

The mechanisms of BRCA-related breast cancer and molecular profiling
21 May 2015 Oncology

Current research into treatments for BRCA-related breast cancer and the phase 3 EMBRACA trial
21 May 2015 Oncology

The role of BRCA and PARP in DNA repair and BRCA-related breast cancer
21 May 2015 Oncology

The phase 3 EMBRACA study of talazoparib in BRCA-related metastatic breast cancer
21 May 2015 Oncology

BRCA-related breast cancer: the implications of genetic testing and potential management options
12 May 2015 Oncology

Dr Keith Stewart chairs a discussion on early treatment and novel therapies for multiple myeloma
12 May 2015 Oncology

Prof Kenneth Anderson chairs a discussion on novel immunotherapies for treating multiple myeloma
12 May 2015 Oncology

Dr Keith Stewart chairs a discussion on tumour biology-guided treatment for multiple myeloma
12 May 2015 Hematology

Clinical significance of progenitor cells in multiple myeloma
12 May 2015 Hematology

An update on the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey
12 May 2015 Oncology

PALOMA-1 study of palbociclib in ER+, HER2-, breast cancer
12 May 2015 Oncology

The importance of the St. Gallen Breast Cancer Conference
12 May 2015 Oncology

An update in breast cancer management at St. Gallen 2015
24 Apr 2015 Oncology

Targeting BCL-2 for treating oestrogen-positive breast cancer
24 Apr 2015 Oncology

Highlights from the St. Gallen Breast Cancer Conference 2015
24 Apr 2015 Oncology

The current biosimilar landscape
24 Apr 2015 Oncology

Biosimilars for breast cancer treatment
24 Apr 2015 Oncology

CDK 4/6 inhibitor, palbociclib, for the treatment of metastatic breast cancer
24 Apr 2015 Oncology

Ki67 as a marker for making management decisions in breast cancer
24 Apr 2015 Oncology

New drugs in neoadjuvant breast cancer therapy
24 Apr 2015 Oncology

Are randomised trials obsolete or more important than ever?
24 Apr 2015 Oncology

An Interview with Prof. Dmitry Pushkar at EAU 2015
14 Apr 2015 Oncology

Immune pathways and immunome as targets for breast cancer treatment
14 Apr 2015 Oncology

Personalised breast cancer treatment
14 Apr 2015 Oncology

ESMO 2014: The collaboration between basic scientists and clinicians
20 Mar 2015 Oncology